Clinical Trial Search

Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L

Primary: Monocyte NfkB Levels as Detected by Western Blotting — 62.79; 72.03; 67.68; 84.19 NfkB p65 arbitrary units

Primary: Change in Mean Glucose (mg/dL) From Baseline — 2.1 mg/dL — p=0.8

Primary: Change in Glycemic Control as Measured by Change Blood Sugar Values — 88.9; 95.4; 90.8; 96.7 mg/dL — p=<0.001

Primary: Ability of Different Screening Tests Which Can be Performed Opportunistically (During Outpatient Visits -- at Any Time of Day, Regardless of Meal Status) to Predict…

Primary: Participant Satisfaction With Continuous Glucose Monitoring (CGM) — 10; 4; 1; 0 participants

Primary: Abnormal Glucose Levels After Colonoscopic Preparation — 2; 0; 185 Participants

Primary: Disposition Index — 708; 793; 791 unitless

Primary: Fasting Glucose — 5.1; 5.9 mmol/L — p=0.005

Primary: Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke — 1.100; 1.096 units on a scale — p=<0.05

Primary: Lowering of Fasting Glucose — 5.78; 5.83 mmol/l — p=>0.05

Primary: Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo — -5.2; -9.4; -8.8 umol/L — p=0.57

Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min

Primary: Number of Patients With a Diagnosis of Gestational Diabetes at 26 Weeks Gestation. — 19; 23 Participants — p=0.32

Primary: Steady State Beta Cell Compensation — 3.01; 3.19 (nmol/L) adjusted for M/I — p=0.05

Primary: Fasting Insulin — 10.26; 10.39 uIU/ml

Primary: Changes in Liver Fat — 5.4; 7.3 percent liver fat — p=0.05

Primary: Number of Participants Diagnosed With Prediabetes or Normal Glucose, by 2 Measurements (Fasting Glucose Measurement and Glucose Measurement After a 2-hour Oral Glucose…

Primary: Monitoring Adverse Events — 0; 0 TEAE

Primary: First-Phase Insulin Release (FPIR) — 264; 339; 197; 359 microunits/ml

Primary: Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index — 1.91; 0.84 units on a scale — p=0.001

Primary: Endogenous Glucose Production — 0.5; 0.84; 0.6; 0.4 mg/kg/min

Primary: Postprandial Glucose Levels at Week 12 — 9.5; 9.9 mmol/L — p=0.380

Primary: GLP-1 Levels in Response to Oral Glucose Tolerance Test — 16.66; 18.57 pmol/l.h — p=0.209

Primary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1

Primary: Number of Participants Recruited and Retained — 8; 9 Participants

Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL

Primary: Body Mass Index (BMI) - Post-Test — 30.3; 28.8 kg/m2

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: Number of PCP Visits Where Ppt Was Referred to Diabetes Prevention Program Within 30 Days of Visit — 47; 10 pcp visits